Fig. 5

Endotoxin does not significantly change the distribution of ApoC-III among plasma lipoproteins. The concentration of (a) apo C-III in plasma, (b) apo C-III associated with HDL (C-III heparin soluble [HS]), (c) apo C-III associated with apo B-containing lipoproteins (C-III heparin precipitate [HP]) was measured at baseline and for 8 h after an intravenous dose of endotoxin (closed circles, n = 11) or saline (open circles, n = 4). (d) Changes in the distribution of apo C-III in HS and HP expressed as the C-III HS/C-III HP ratio (apo C-III R) after the intravenous injection of endotoxin (LPS). Data were analyzed by 2-way repeated measures ANOVA (time x LPS treatment) with Dunnett’s posthoc analysis for time points compared to baseline in saline (+; p < 0.05) or LPS (#; p < 0.05). A Sidak’s multiple comparison test was used to compare treatment groups within each time point (*; p < 0.05)